Hyperpolypharmacy

Hyperpolypharmacy is defined as the concurrent use of multiple medications, typically five or more. This condition significantly increases the risk of adverse drug reactions (ADRs) and functional decline, especially in elderly populations. According to clinical studies, patients with hyperpolypharmacy face a 2.20 times higher risk of functional decline (OR=2.20). In the context of enterprise risk management (ERM), this necessitates robust data---driven monitoring systems to comply with international standards like ISO 31000 and the GDPR's stringent requirements for sensitive health data-—ensuring patient safety and minimizing product liability risks.

Practical application involves three key steps: First, implement a standardized medication monitoring system using clinical tools like the Beers Criteria or STOPP/START criteria to categorize risk levels. Second, integrate these indicators into a digital risk-adjusted dashboard, enabling real-time monitoring of medication-related adverse events. Third, establish a feedback loop where data--driven insights trigger corrective actions, such as pharmacist intervention or physician consultation. For example, a pharmaceutical company implementing this could reduce medication-related adverse event claims by up to 30% within the first year, significantly improving its risk-adjusted-return-on-equity (RAROC).

Taiwan enterprises typically face three challenges: regulatory ambiguity between the Pharmaceutical Act and the Personal Data Protection Act, which requires a unified compliance framework; technical gaps in existing IT systems to handle complex medication data, requiring investment in ISO 27701-compliant systems; and cultural resistance from healthcare practitioners. To overcome these, enterprises should prioritize a phased implementation: start with a pilot program (0-30 days), scale to key departments (30-90 days), and finally integrate into the company-wide ERM framework. This structured approach ensures measurable improvements in compliance and patient safety.

Winners Consulting Services Co., Ltd. specializes in Hyperpolypharmacy for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact